PERCEPTIVE ADVISORS LLC
13F Reported Value
ⓘ$6.7B
incl. option notional
Equity Holdings
ⓘ$6.4B
Option Notional
ⓘ$221.3M
$197.2M puts / $24.1M calls
Holdings
109
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
PERCEPTIVE ADVISORS LLC disclosed 109 positions worth $6.7B in its Form 13F-HR for Q2 2026 — $6.4B in common stock plus $221.3M of put/call option positions (reported at underlying notional value, not premium at risk), led by $PRAX (Praxis Precision Medicines, Inc.) at 10.6% of the equity portfolio, followed by $SYRE and $CELC. During the quarter the fund opened 27 new positions and exited 12 — including a new stake in $KARD and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (99.2% of disclosed assets). All figures are sourced directly from PERCEPTIVE ADVISORS LLC’s Form 13F-HR filing with the SEC under CIK 1224962.
AI Fund Analysis
Diversifying
$PRAX
$SYRE
$CELC
$RYTM
$ROIV
$NRIX
$ZYME$SYRE
$RLAY
$TNGXSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $681.6M2,035,986 sh
- —
Quality
$383.5M4,319,496 sh - —
Quality
$334.5M3,197,200 sh - 44.8
Quality
$310.4M1,163,721 sh - 33.9
Quality
$287.2M2,586,295 sh - —
Quality
$286.1M8,085,461 sh - 19.5
Quality
$263.9M14,106,187 sh - 56.6
Quality
$213.2M3,752,574 sh - —
Quality
$195.6M8,200,662 sh - —
Quality
$195.2M1,580,505 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| Praxis Precision Medicines, Inc.$PRAX | — | $681.6M | 2,035,986 |
| Spyre Therapeutics, Inc.$SYRE | — | $383.5M | 4,319,496 |
| Celcuity Inc.$CELC | — | $334.5M | 3,197,200 |
 Ascendis Pharma A/S$ASND | 44.8 | $310.4M | 1,163,721 |
| RHYTHM PHARMACEUTICALS, INC.$RYTM | 33.9 | $287.2M | 2,586,295 |
| Roivant Sciences Ltd.$ROIV | — | $286.1M | 8,085,461 |
| Relay Therapeutics, Inc.$RLAY | 19.5 | $263.9M | 14,106,187 |
 Travere Therapeutics, Inc.$TVTX | 56.6 | $213.2M | 3,752,574 |
 Kardigan, Inc.$KARD | — | $195.6M | 8,200,662 |
 Nuvalent, Inc.$NUVL | — | $195.2M | 1,580,505 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of PERCEPTIVE ADVISORS LLC's 109 positions.
Showing top 10 of 109 holdings.
Sector Allocation
Healthcare
$6.4B
Technology
$46.5M
Financials
$8.0M
Full Holdings — PERCEPTIVE ADVISORS LLC (Q2 2026)
All 109 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $681.6M | 10.6% | +0% | — |
| 2 | $SYRE | Spyre Therapeutics, Inc. | $383.5M | 6.0% | +14% | — |
| 3 | $CELC | Celcuity Inc. | $334.5M | 5.2% | +2% | — |
| 4 | $ASND | Ascendis Pharma A/S | $310.4M | 4.8% | -24% | 44.8 |
| 5 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $287.2M | 4.5% | +9% | 33.9 |
| 6 | $ROIV | Roivant Sciences Ltd. | $286.1M | 4.4% | -2% | — |
| 7 | $RLAY | Relay Therapeutics, Inc. | $263.9M | 4.1% | +45% | 19.5 |
| 8 | $TVTX | Travere Therapeutics, Inc. | $213.2M | 3.3% | -9% | 56.6 |
| 9 | $KARD | Kardigan, Inc. | $195.6M | 3.0% | NEW | — |
| 10 | $NUVL | Nuvalent, Inc. | $195.2M | 3.0% | +0% | — |
| 11 |  $EWTX | Edgewise Therapeutics, Inc. | $177.7M | 2.8% | -1% | — |
| 12 |  $APGE | Apogee Therapeutics, Inc. | $173.6M | 2.7% | -15% | — |
| 13 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $149.7M | 2.3% | +1% | 8.7 |
| 14 |  $MGTX | MeiraGTx Holdings plc | $145.7M | 2.3% | +4% | — |
| 15 |  $ORKA | Oruka Therapeutics, Inc. | $128.0M | 2.0% | -4% | — |
| 16 |  $INBX | Inhibrx Biosciences, Inc. | $123.0M | 1.9% | -10% | 30 |
| 17 |  $PTGX | Protagonist Therapeutics, Inc | $120.4M | 1.9% | -20% | 59.4 |
| 18 |  $SLDB | Solid Biosciences Inc. | $118.9M | 1.9% | +0% | — |
| 19 | $ZYME | Zymeworks Inc. | $109.3M | 1.7% | +19% | 8.7 |
| 20 | $TNGX | Tango Therapeutics, Inc. | $105.6M | 1.6% | +318% | 17.6 |
| 21 |  $IMTX | Immatics N.V. | $105.2M | 1.6% | +0% | — |
| 22 | $NRIX | Nurix Therapeutics, Inc. | $104.8M | 1.6% | +16% | 6.4 |
| 23 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $103.1M | 1.6% | +39% | 53.2 |
| 24 |  $RVMD | Revolution Medicines, Inc. | $98.8M | 1.5% | +104% | — |
| 25 |  $AVLN | Avalyn Pharma Inc. | $88.1M | 1.4% | NEW | — |
| 26 |  $MRNAPUT | Moderna, Inc. | $70.0M | — | +0% | 21.2 |
| 27 |  $DYN | Dyne Therapeutics, Inc. | $59.7M | 0.9% | -42% | — |
| 28 |  $BIIB | BIOGEN INC. | $59.7M | 0.9% | NEW | 64.7 |
| 29 |  $IMVT | Immunovant, Inc. | $52.3M | 0.8% | -15% | — |
| 30 |  $UNH | UNITEDHEALTH GROUP INC | $48.5M | 0.8% | NEW | 62.7 |
| 31 | — | SPDR SERIES TRUST - ST STR SP BIOT | $47.5M | — | NEW | — |
| 32 |  $IONS | IONIS PHARMACEUTICALS INC | $44.9M | 0.7% | +12% | 23.4 |
| 33 |  $STRO | SUTRO BIOPHARMA, INC. | $43.3M | 0.7% | +82% | 15.3 |
| 34 |  $ANRO | Alto Neuroscience, Inc. | $42.5M | 0.7% | -20% | — |
| 35 |  $JAZZ | Jazz Pharmaceuticals plc | $41.0M | 0.6% | +0% | — |
| 36 |  $CRVS | Corvus Pharmaceuticals, Inc. | $39.9M | 0.6% | +16% | — |
| 37 |  $SION | Sionna Therapeutics, Inc. | $39.8M | 0.6% | +37% | — |
| 38 |  $CTMX | CytomX Therapeutics, Inc. | $39.1M | 0.6% | +3% | 8.7 |
| 39 |  $AORT | ARTIVION, INC. | $39.0M | 0.6% | +6% | 48.1 |
| 40 |  $XFOR | X4 Pharmaceuticals, Inc | $37.0M | 0.6% | +18% | 28 |
| 41 |  $CORT | CORCEPT THERAPEUTICS INC | $34.6M | 0.5% | +697% | 57.8 |
| 42 |  $RGEN | REPLIGEN CORP | $33.9M | 0.5% | -12% | 58.4 |
| 43 |  $AVR | Anteris Technologies Global Corp. | $33.7M | 0.5% | +0% | — |
| 44 |  $RAPP | Rapport Therapeutics, Inc. | $32.2M | 0.5% | +15% | — |
| 45 |  $DMRA | Damora Therapeutics, Inc. | $31.8M | 0.5% | +0% | — |
| 46 |  $CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $31.8M | 0.5% | NEW | 43.8 |
| 47 |  $AXSM | Axsome Therapeutics, Inc. | $29.0M | 0.5% | -21% | 40.8 |
| 48 |  $EYPTPUT | EyePoint, Inc. | $28.6M | — | NEW | 3.5 |
| 49 |  $DBVT | DBV Technologies S.A. | $27.1M | 0.4% | +71% | — |
| 50 |  $IRTC | iRhythm Holdings, Inc. | $26.6M | 0.4% | +113% | 54.8 |
| 51 |  $ADPT | Adaptive Biotechnologies Corp | $26.1M | 0.4% | +698% | 41.4 |
| 52 |  $SABS | SAB Biotherapeutics, Inc. | $25.8M | 0.4% | +3% | — |
| 53 |  $DHR | DANAHER CORP /DE/ | $24.8M | 0.4% | NEW | 64.8 |
| 54 |  $TENX | TENAX THERAPEUTICS, INC. | $24.7M | 0.4% | +17% | — |
| 55 |  $CAPRCALL | CAPRICOR THERAPEUTICS, INC. | $24.1M | — | NEW | 13.6 |
| 56 |  $SLSPUT | SELLAS Life Sciences Group, Inc. | $22.1M | — | NEW | — |
| 57 |  $NAUT | Nautilus Biotechnology, Inc. | $21.8M | 0.3% | -8% | — |
| 58 |  $OBIO | Orchestra BioMed Holdings, Inc. | $21.7M | 0.3% | +0% | 32 |
| 59 |  $ISRG | INTUITIVE SURGICAL INC | $20.6M | 0.3% | -39% | 79.9 |
| 60 |  $ANL | Adlai Nortye Group Ltd. | $20.6M | 0.3% | NEW | — |
| 61 |  $CTNM | Contineum Therapeutics, Inc. | $20.6M | 0.3% | +0% | — |
| 62 |  $NVCT | Nuvectis Pharma, Inc. | $18.4M | 0.3% | NEW | — |
| 63 |  $PALI | PALISADE BIO, INC. | $17.6M | 0.3% | -6% | — |
| 64 |  $OMDA | Omada Health, Inc. | $17.3M | 0.3% | +0% | 59.4 |
| 65 |  $LONA | LeonaBio, Inc. | $17.1M | 0.3% | +0% | — |
| 66 |  $EOLS | Evolus, Inc. | $17.1M | 0.3% | +91% | 39 |
| 67 |  $NAMSPUT | NewAmsterdam Pharma Co N.V. | $16.9M | — | NEW | — |
| 68 |  $IVVD | Invivyd, Inc. | $16.1M | 0.3% | -11% | 29.7 |
| 69 | $CELC | Celcuity Inc. | $14.6M | 0.2% | +0% | — |
| 70 |  $MIRM | Mirum Pharmaceuticals, Inc. | $13.5M | 0.2% | NEW | 35 |
| 71 |  $SRZN | Surrozen, Inc./DE | $13.1M | 0.2% | +120% | — |
| 72 |  $BBNX | Beta Bionics, Inc. | $13.1M | 0.2% | -1% | 29.8 |
| 73 | $CAPRPUT | CAPRICOR THERAPEUTICS, INC. | $12.0M | — | NEW | 13.6 |
| 74 |  $AXGN | Axogen, Inc. | $11.4M | 0.2% | -65% | 40.8 |
| 75 |  $OSCR | Oscar Health, Inc. | $11.4M | 0.2% | NEW | 83.1 |
| 76 |  $OCS | Oculis Holding AG | $11.2M | 0.2% | +64% | — |
| 77 |  $SPTX | Seaport Therapeutics, Inc. | $10.9M | 0.2% | NEW | — |
| 78 |  $VRDN | Viridian Therapeutics, Inc.\DE | $10.7M | 0.2% | -50% | 27.2 |
| 79 |  $BSX | BOSTON SCIENTIFIC CORP | $10.7M | 0.2% | NEW | 77.5 |
| 80 |  $BLLN | BillionToOne, Inc. | $10.4M | 0.2% | -5% | 61.9 |
| 81 |  $ABVX | Abivax S.A. | $9.9M | 0.1% | -77% | — |
| 82 |  $NTRA | Natera, Inc. | $9.4M | 0.1% | NEW | 53.5 |
| 83 |  $ENGN | enGene Therapeutics Inc. | $8.3M | 0.1% | -17% | — |
| 84 |  $RACC | Research Alliance Corp III | $8.0M | 0.1% | NEW | — |
| 85 |  $AGMB | Agomab Therapeutics NV | $7.8M | 0.1% | +0% | — |
| 86 |  $CGEM | Cullinan Therapeutics, Inc. | $7.8M | 0.1% | NEW | — |
| 87 |  $QURE | uniQure N.V. | $7.7M | 0.1% | NEW | — |
| 88 |  $MOBI | Mobia Medical, Inc. | $7.0M | 0.1% | NEW | — |
| 89 |  $ADGM | Adagio Medical Holdings, Inc. | $6.4M | 0.1% | +161% | — |
| 90 |  $GH | Guardant Health, Inc. | $6.2M | 0.1% | -86% | 39 |
| 91 |  $PHAT | Phathom Pharmaceuticals, Inc. | $5.8M | 0.1% | -42% | 40.9 |
| 92 |  $OTLK | Outlook Therapeutics, Inc. | $5.0M | 0.1% | NEW | 23.5 |
| 93 |  $COGT | Cogent Biosciences, Inc. | $4.7M | 0.1% | +0% | — |
| 94 |  $EDSA | Edesa Biotech, Inc. | $4.6M | 0.1% | +0% | — |
| 95 |  $AVTX | Avalo Therapeutics, Inc. | $4.1M | 0.1% | +57% | 11.7 |
| 96 |  $TWST | Twist Bioscience Corp | $3.8M | 0.1% | -75% | 33.9 |
| 97 |  $CBIO | CRESCENT BIOPHARMA, INC. | $3.7M | 0.1% | +0% | 9.6 |
| 98 |  $XERS | Xeris Biopharma Holdings, Inc. | $3.7M | 0.1% | NEW | 56.5 |
| 99 |  $OM | Outset Medical, Inc. | $3.6M | 0.1% | +0% | 18.5 |
| 100 |  $BDSX | BIODESIX INC | $2.5M | 0.0% | NEW | 35 |
| 101 | $RVMD | Revolution Medicines, Inc. | $2.3M | 0.0% | +0% | — |
| 102 |  $CNTB | Connect Biopharma Holdings Ltd | $1.9M | 0.0% | +0% | — |
| 103 |  $KPRX | KIORA PHARMACEUTICALS INC | $1.2M | 0.0% | NEW | — |
| 104 |  $MDLN | Medline Inc. | $1.1M | 0.0% | +0% | 62.5 |
| 105 |  $ADMA | ADMA BIOLOGICS, INC. | $952,213 | 0.0% | -76% | 69.7 |
| 106 |  $CPIX | CUMBERLAND PHARMACEUTICALS INC | $628,443 | 0.0% | -51% | 20.1 |
| 107 |  $XGN | EXAGEN INC. | $534,252 | 0.0% | +0% | 27.3 |
| 108 |  $ENSC | Ensysce Biosciences, Inc. | $25,133 | 0.0% | +0% | — |
| 109 | $SRZN | Surrozen, Inc./DE | $2,750 | 0.0% | +0% | — |
New Positions (27)
$KARD Kardigan, Inc.$195.6M$AVLN Avalyn Pharma Inc.$88.1M$BIIB BIOGEN INC.$59.7M$UNH UNITEDHEALTH GROUP INC$48.5M$CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.$31.8M$EYPTPUT EyePoint, Inc.$28.6M$DHR DANAHER CORP /DE/$24.8M$CAPRCALL CAPRICOR THERAPEUTICS, INC.$24.1M$SLSPUT SELLAS Life Sciences Group, Inc.$22.1M$ANL Adlai Nortye Group Ltd.$20.6M$NVCT Nuvectis Pharma, Inc.$18.4M$NAMSPUT NewAmsterdam Pharma Co N.V.$16.9M$MIRM Mirum Pharmaceuticals, Inc.$13.5M$CAPRPUT CAPRICOR THERAPEUTICS, INC.$12.0MExited Positions (12)
$CNTA Centessa Pharmaceuticals plc
$DAWN Day One Biopharmaceuticals, Inc.
$DRUG BRIGHT MINDS BIOSCIENCES INC.
$BLTE BELITE BIO, INC
$EVMN Evommune, Inc.
$NMRA Neumora Therapeutics, Inc.
$NBIX NEUROCRINE BIOSCIENCES INC
$IRD Opus Genetics, Inc.
$OCULCALL OCULAR THERAPEUTIX, INC
$IKT Inhibikase Therapeutics, Inc.
$APLS Apellis Pharmaceuticals, Inc.
$PTN PALATIN TECHNOLOGIES INCBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for PERCEPTIVE ADVISORS LLC including:
Track PERCEPTIVE ADVISORS LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for PERCEPTIVE ADVISORS LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: PERCEPTIVE ADVISORS LLC
13F Pro is an AI hedge fund tracker and stock research platform. For PERCEPTIVE ADVISORS LLC (SEC CIK: 1224962), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in PERCEPTIVE ADVISORS LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.